HER2/neu may not be an interesting target in biliary cancers: Results of an early phase II Study with Lapatinib

Oncology

Volumn 82, Issue 3, 2012, Pages 175-179

  Peck, Joshua ^a   Wei, Lai ^a   Zalupski, Mark ^b   O'Neil, Bert ^c   Villalona Calero, Miguel ^a   Bekaii Saab, Tanios ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Biliary cancer; Epidermal growth factor receptor; HER2 neu; Lapatinib

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB;

ABDOMINAL PAIN; ADULT; AGED; AGITATION; ANOREXIA; ARTHRALGIA; ARTICLE; BILE DUCT CANCER; BLOATING; BLOOD SAMPLING; CANCER STAGING; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CONSTIPATION; DIARRHEA; DIZZINESS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DYSGEUSIA; EXON; FATIGUE; FEMALE; FOLLOW UP; FRACTURE; HUMAN; HYPERCALCEMIA; HYPOALBUMINEMIA; HYPOKALEMIA; HYPONATREMIA; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NECK PAIN; PAIN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIDE EFFECT; STOMACH OBSTRUCTION; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BILIARY TRACT NEOPLASMS; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MUTATION; NEOPLASM METASTASIS; PROGNOSIS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; SURVIVAL RATE;

EID: 84858321104     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000336488     Document Type: Article

References (21)

1. Jemal A, Siegel R, Xu J, Ward E: Cancer statistics. CA Cancer J Clin 2010; 60: 277-300.
2. Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira SP, Roughton M, Bridgewater J: Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010; 362: 1273-1281.
3. Schottenfeld D, Fraumeni J: Cancer Epidemiology and Prevention, ed 3. New York, Oxford University Press, 2006.
4. Pignochino Y, Sarotto I, Peraldo-Neia C, Penachioni J, Cavalloni G, Migliardi G, Casorzo L, Chiorino G, Risio M, Bardelli A, Aglietta M, Leone F: Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas. BMC Cancer 2010; 10: 631.
5. Philip PA, Mahoney MR, Allmer C, Thomas J, Pitot HC, Kim G, Donehower RC, Fitch T, Picus J, Erlichman C: Phase II study of erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J Clin Oncol 2005; 23: 6657-6663. (Pubitemid 46190260)
6. Lee SC, Lim SG, Soo R, Hsieh WS, Guo JY, Putti T, Tao Q, Soong R, Goh BC: Lack of somatic mutations in EGFR tyrosine kinase domain in hepatocellular and nasopharyngeal carcinoma. Pharmacogenet Genom 2006; 16: 73-74. (Pubitemid 41803879)
7. Yoon J, Gwak G, Lee H, Bronk SF, Werneburg NW, Gores GJ: Enhanced epidermal growth factor receptor activation in human cholangiocarcinoma cells. J Hepatol 2004; 41: 808-814. (Pubitemid 39434311)
8. Werneburg NW, Yoon J, Higuchi H, Gores GJ: Bile acids activate EGF receptor via a TGF-dependent mechanism in human cholangiocyte cell lines. Am J Physiol Gastrointest Liver Physiol 2003; 285:G31-G36. (Pubitemid 36736385)
9. Nakazawa K, Dobashi Y, Suzuki S, Fujii H, Takeda Y, Ooi A: Amplification and overexpression of c-erbB-2, epidermal growth factor receptor, and c-met in biliary tract cancers. J Pathol 2005; 206: 356-365. (Pubitemid 40903200)
10. Rusnak DW, Lackey K, Affleck K, Wood ER, Alligood KJ, Rhodes N, Keith BR, Murray DM, Knight WB, Mullin RJ, Gilmer TM: The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Ther 2001; 1: 85-94.
11. Shewchuk L, Hassell A, Wisely B, Rocque W, Holmes W, Veal J, Kuype LF: Binding mode of the 4-anilinoquinazoline class of protein kinase inhibitor: X-ray crystallographic studies of 4-anilinoquinazolines bound to cyclin-dependent kinase 2 and p38 kinase. J Med Chem 2000; 43: 133-138. (Pubitemid 30055770)
12. Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, Jagiello-Gruszfeld A, Crown J, Chan A, Kaufman B, Skarlos D, Campone M, Davidson N, Berger M, Oliva C, Rubin SD, Stein S, Cameron D: Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006; 355: 2733-2743. (Pubitemid 46021510)
13. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92: 205-216. (Pubitemid 30099779)
14. Bekaii-Saab T, Markowitz J, Prescott N, Sadee W, Heerema N, Wei L, Dai Z, Papp A, Campbell A, Culler K, Balint C, O'Neil B, Lee R, Zalupski M, Dancey J, Chen H, Grever M, Eng C, Villalona-Calero M: A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas. Clin Cancer Res 2009; 15: 5895-5901.
15. Bekaii-Saab T, Williams N, Plass C, Calero M, Eng C: A novel mutation in the tyrosine kinase domain of ERBB2 in hepatocellular carcinoma. BMC Cancer 2006; 6: 278.
16. Ramanathan RK, Belani CP, Singh DA, Tanaka M, Lenz HJ, Yen Y, Kindler HL, Iqbal S, Longmate J, Mack PC, Lurje G, Gandour-Edwards R, Dancey J, Gandara DR: A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer. Cancer Chemother Pharmacol 2009; 64: 777-783.
17. Harder J, Waiz O, Otto F, Geissler M, Olschewski M, Weinhold B, Blum HE, Schmitt-Graeff A, Opitz OG: EGFR and HER2 expression in advanced biliary tract cancer. World J Gastroenterol 2009; 15: 4511-4517.
18. Ukita Y, Kato M, Terada T: Gene amplification and mRNA and protein overexpression of c-erbB-2 (HER-2/neu) in human intrahepatic cholangiocarcinoma as detected by fluorescence in situ hybridization, in situ hybridization, and immunohistochemistry. J Hepatol 2002; 36: 780-785. (Pubitemid 35177407)
19. Bekaii-Saab T, Phelps MA, Li X, Saji M, Goff L, Kauh JSW, O'Neil BH, Balsom S, Balint C, Liersemann R, Vasko VV, Bloomston M, Marsh W, Doyle LA, Ellison G, Grever M, Ringel MD, Villalona-Calero MA: Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers. J Clin Oncol 2011; 29: 2357-2363.
20. Zhu AX, Hezel AF: Development of molecularly targeted therapies in biliary tract cancers: reassessing the challenges and opportunities. Hepatology 2011; 53: 695-704.
21. Rennie D: Disclosure to the reader of institutional review board approval and informed consent. J Am Med Assoc 1997; 277: 922-923. (Pubitemid 27123955)